



Crimped Percutaneous Valve




"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Percutaneous Heart Valve (PHV)



T.E.E. OF THV FUNCTION



**5 months post-implantation
in descending aorta**

 Edwards Lifesciences

"PROTECTIVE ORDER MATERIAL"

Heroic Therapy

Redacted -- Not Responsive




"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 39 of 69
EDWARDS 02433181

Percutaneous Valve Technologies, Inc. (PVT)

➤ December-2002




"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 40 of 69
EDWARDS 02433182

Cribier-Edwards Aortic PHV




Edwards Lifesciences


"PROTECTIVE ORDER MATERIAL"

Highly Confidential





Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 41 of 69
EDWARDS 02433163



25




"PROTECTIVE ORDER MATERIAL"



ciences

"PROTECTIVE ORDER MATERIAL"

Computational Fluid Dynamic Study of THV



"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 44 of 69
EDWARDS 02433186

Percutaneous Valve Technologies, Inc. (PVT)

- ◆ **December-2003 Edwards Announcement**
 - Acquisition of PVT at \$125M with \$30M earnout
- ◆ Deal closed January 21, 2004



"PROTECTIVE ORDER MATERIAL"

Edwards Lifesciences Corporation, et al., Exhibit 1060, p. 45 of 69
EDWARDS 02433187

Highly Confidential

Edwards SAPIEN® Transcatheter Aortic Heart Valves*

Global Clinical Experience

Over 2,500 patients enrolled
in clinical studies to date

Clinical Studies

- Prospective, Multi-center, Adjudicated, Feasibility
- Prospective, Multi-center, Adjudicated, Post-Market
- Prospective, Multi-center, Adjudicated, Randomized

PREVAILEU™

PARTNER IDE

SOURCE

PARTNER EU

REVIVAL II

TRAVERCE

REVIVE II

IREVIVE

RECAST

2004

© 2004 Edwards Lifesciences Corporation. All rights reserved. SAPIEN, PARTNER, TRAVERCE, REVIVE, IREVIVE, REVIVAL, and RECAST are trademarks of Edwards Lifesciences Corporation. PREVAILEU, PARTNER IDE, SOURCE, and REVIVAL II are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

*PROTECTIVE ORDER MATERIAL

October 21, 2010

The NEW ENGLAND
JOURNAL of MEDICINE

Transcatheter Aortic-Valve Implantation for Aortic Stenosis
in Patients Who Cannot Undergo Surgery

Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D.,
Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D.,
Raj R. Makkar, M.D., David L. Brown, M.D., Peter C. Block, M.D., Robert A. Guyton, M.D.,
Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D., Howard C. Herrmann, M.D., Pamela C. Douglas, M.D.,
John L. Petersen, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D.,
and Stuart Pocock, Ph.D., for the PARTNER Trial Investigators*




Edwards Lifesciences

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit USO, p. 47 of 69
EDWARDS 02433189

All Cause Mortality



Numbers at Risk	0	6	12	18	24
TAVI	179	136	122	67	26
Standard Rx	179	121	83	41	12

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

**The NEW ENGLAND
JOURNAL of MEDICINE**

ESTABLISHED IN 1812

JUNE 9, 2011

VOL. 364 NO. 23

**Transcatheter versus Surgical Aortic-Valve Replacement
in High-Risk Patients**

Craig R. Smith, M.D., Martin B. Leon, M.D., Michael J. Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D.,
Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D., John G. Webb, M.D., Gregory P. Fontana, M.D.,
Raj R. Makkar, M.D., Mathew Williams, M.D., Todd Dewey, M.D., Samir Kapadia, M.D., Vasilis Babaliaros, M.D.,
Vinod H. Thourani, M.D., Paul Corso, M.D., Augusto D. Pichard, M.D., Joseph E. Bavaria, M.D.,
Howard C. Herrmann, M.D., Jodi J. Akin, M.S., William N. Anderson, Ph.D., Duolao Wang, Ph.D.,
and Stuart J. Pocock, Ph.D., for the PARTNER Trial investigators*

ABSTRACT


 Edwards Lifesciences

PROTECTIVE ORDER MATERIAL

Edwards Lifesciences Corporation, et al., Exhibit 1059, p. 49 of 69
EDWARDS 02433191

Highly Confidential

All-Cause Mortality Transfemoral (N=492)






Smith et al, NEJM, June 2011

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al, Exhibit 1059, p. 50 of 69
EDWARDS 02433192

Change in QOL (KCCQ): TAVR vs Standard Rx



Cohen et al ICT 2010




MCID = minimum clinically important difference

The drive for Superior Clinical Outcomes resulted in Meaningful Product Iterations and New Product Platforms

Clinical Evidence Generation

Improvement outcomes
Iterative product design

Expansion of indication
Learning curve




"PROTECTIVE ORDER MATERIAL"

Highly Confidential


Edwards Lifesciences Corporation, et al. Exhibit 1059, p. 57 of 69
EDWARDS 02433194

Edwards will have a very robust THV Product Portfolio


SAPIEN



RetroFlex 3




Ascendra 3




Product development complete


SAPIEN XT



NovaFlex+




Ascendra+





Product development complete

SAPIEN 3




SAPIEN 3
Transfemoral,
Transapical,
Transaortic





CE Mark Pending

CENTERA



CENTERA
Transfemoral,
Subclavian



Complete Clinical trial in 2014

Future Techno

SAPIEN 3 P (DS)


CENTERA Upgrade

CENTERA N

SAPIEN NX

Redacted – Not Responsive

AT is set-up similar to a start-up and focused
on innovative programs in SHD



"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1059, p. 54 of 69
EDWARDS 02433196

INTUITY Has the Potential to Expand Minimally Invasive Valve Surgery Options




THV
Learnings

+




Proven
Technology

=



Edwards INTUITY™
Valve System



1/11/11


7
Edwards

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 55 of 69
EDWARDS 02433197

Population of Left Sided Valvular Heart Disease (Euro Heart Survey)



Lang et al. A Prospective survey of Patients with Valvular Heart Disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *European Heart Journal*, 2003;24:1231-1243.

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 56 of 69
EDWARDS 02433198


Redacted -- Not Responsive

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation et al., Exhibit 1824, p. 57 of 69
EDWARDS 02433199

Dedicated delivery catheter



 Edwards Lifesciences

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1059, p. 38 of 49
EDWARDS 02433200

18th Feb 2014

FIM TMVI with the Edwards Fortis system



Edwards Lifesciences

"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1059, p. 59 of 69
EDWARDS 02433201



"PROTECTIVE ORDER MATERIAL"

Redacted -- Not Responsive

Redacted -- Not Responsive

"PROTECTIVE ORDER MATERIAL"

Highly Confidential


Edwards Lifesciences Corporation et al., Exhibit 1059, p. 65 of 69
EDWARDS 02433204

Redacted -- Not Responsive

Procedural times

Procedure time in minutes
(Apical puncture to retrieval)

■ Procedure time





Lessons learnt from the first 4 patients

- **Patient selection:** not dissimilar to the TAVI story! Maybe different for the mitral. Factors including degree of LV dysfunction, pulmonary disease, renal disease, redo surgery etc. The mitral patient may require longer to see benefit than the aortic.

Redacted -- Not Responsive


- **Procedure:** predominantly echo guided. Good 2/3D TOE images vital. Imaging guided selection of apical puncture site. Ensure no chordal entanglement of crossing wire. Crucial aspect is convincing P2 capture confirmed by echo.
- **Post procedure:** anti-coagulation.

Redacted -- Not Responsive



Edwards


Helping Patients is Our Life's Work, and
life is now



"PROTECTIVE ORDER MATERIAL"

Highly Confidential

Edwards Lifesciences Corporation, et al., Exhibit 1050, p. 68 of 69
EDWARDS 02433210



"PROTECTIVE ORDER MATERIAL"